ROS-responsive chitosan-SS31 prodrug for AKI therapy via rapid distribution in the kidney and long-term retention in the renal tubule.

Liu D, Shu G, Jin F, Qi J, Xu X, Du Y, Yu H, Wang J, Sun M, Sun M, You Y, Zhu M and 7 more

Show all authors

Chen M, Zhu L, Shen Q, Ying X, Lou X, Jiang S, Du Y

Science advances9 Oct 2020Cited by 172 (Europe PMC)

PMID33036968PMCIDPMC7546709DOI10.1126/sciadv.abb7422PepBankPUB-33036968

Read at source PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In ischemia-reperfusion AKI, the SC-TK-SS31 conjugate protected mitochondria from damage.
In plain wordsIn an acute kidney injury model, a chitosan-SS31 conjugate protected mitochondria from damage.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseMitochondrial damage
Study
n: not reported in source
ischemia-reperfusion-induced AKI kidneys
Outcome group
Mitochondrial function · Kidney and urinary
Source sentences
Summary
Because of the effective renal distribution combined with ROS-responsive drug release behavior, the administration of SC-TK-SS31 led to an enhanced therapeutic effect of SS31 by protecting mitochondria from damage and reducing the oxidative stress, inflammation, and cell apoptosis.
1 context sentence(design, population, supporting numbers)
Summary · context
SC-TK-SS31 was then prepared by conjugating SS31, a mitochondria-targeted antioxidant, to SC via reactive oxygen species (ROS)-sensitive thioketal linker.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3303696801
02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In ischemia-reperfusion AKI, the SC-TK-SS31 conjugate reduced oxidative stress.
In plain wordsIn an acute kidney injury model, a chitosan-SS31 conjugate lowered oxidative stress.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseOxidative stress
Study
n: not reported in source
ischemia-reperfusion-induced AKI kidneys
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Because of the effective renal distribution combined with ROS-responsive drug release behavior, the administration of SC-TK-SS31 led to an enhanced therapeutic effect of SS31 by protecting mitochondria from damage and reducing the oxidative stress, inflammation, and cell apoptosis.
1 context sentence(design, population, supporting numbers)
Summary · context
SC-TK-SS31 was then prepared by conjugating SS31, a mitochondria-targeted antioxidant, to SC via reactive oxygen species (ROS)-sensitive thioketal linker.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3303696802
03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In ischemia-reperfusion AKI, the SC-TK-SS31 conjugate reduced inflammation.
In plain wordsIn an acute kidney injury model, a chitosan-SS31 conjugate lowered inflammation.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseInflammation
Study
n: not reported in source
ischemia-reperfusion-induced AKI kidneys
Outcome group
Inflammation markers · Kidney and urinary
Source sentences
Summary
Because of the effective renal distribution combined with ROS-responsive drug release behavior, the administration of SC-TK-SS31 led to an enhanced therapeutic effect of SS31 by protecting mitochondria from damage and reducing the oxidative stress, inflammation, and cell apoptosis.
1 context sentence(design, population, supporting numbers)
Summary · context
SC-TK-SS31 was then prepared by conjugating SS31, a mitochondria-targeted antioxidant, to SC via reactive oxygen species (ROS)-sensitive thioketal linker.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3303696803
04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In ischemia-reperfusion AKI, the SC-TK-SS31 conjugate reduced cell apoptosis.
In plain wordsIn an acute kidney injury model, a chitosan-SS31 conjugate reduced cell death.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseCell apoptosis
Study
n: not reported in source
ischemia-reperfusion-induced AKI kidneys
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Because of the effective renal distribution combined with ROS-responsive drug release behavior, the administration of SC-TK-SS31 led to an enhanced therapeutic effect of SS31 by protecting mitochondria from damage and reducing the oxidative stress, inflammation, and cell apoptosis.
1 context sentence(design, population, supporting numbers)
Summary · context
SC-TK-SS31 was then prepared by conjugating SS31, a mitochondria-targeted antioxidant, to SC via reactive oxygen species (ROS)-sensitive thioketal linker.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3303696804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.